Walter H M L Luyten

Title: Walter H M L Luyten: Innovator in Human Checkpoint Kinase Research

Introduction

Walter H M L Luyten is a notable inventor based in Beerse, Belgium. He has made significant contributions to the field of biotechnology, particularly in the area of human checkpoint kinases. With a total of 4 patents to his name, Luyten's work has advanced our understanding of critical biological processes.

Latest Patents

Luyten's latest patents focus on the human checkpoint kinase gene, hCDS1. The first patent describes a novel human checkpoint kinase gene, hCDS1, which includes the nucleic acid sequence of residues 66-1694 of SEQ ID NO: 1. This invention encompasses a protein expressed from the gene, along with fragments and functional equivalents of the protein. Additionally, it provides for pharmaceutical compositions that utilize the hCDS1 protein and methods for employing this protein in various applications. The second patent also pertains to the hCDS1 gene, detailing its translated protein, compositions, methods, and kits designed for practical use.

Career Highlights

Throughout his career, Luyten has worked with prestigious organizations, including The Scripps Research Institute and Janssen Pharmaceutica. His research has been pivotal in the development of innovative therapeutic strategies targeting human diseases.

Collaborations

Luyten has collaborated with esteemed colleagues such as Andrew E Parker and Clare H McGowan. These partnerships have further enriched his research and contributed to the advancement of knowledge in his field.

Conclusion

Walter H M L Luyten stands out as a significant figure in the realm of biotechnology, particularly for his work on human checkpoint kinases. His patents and collaborations reflect his commitment to advancing scientific understanding and developing new therapeutic approaches.